153 related articles for article (PubMed ID: 35352847)
21. Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma.
Henckens SPG; Liu D; Gisbertz SS; Kalff MC; Anderegg MCJ; Crull D; Daams F; van Dalsen AD; Dekker JWT; van Det MJ; van Duijvendijk P; Eshuis WJ; Groenendijk RPR; Haveman JW; van Hillegersberg R; Luyer MDP; Olthof PB; Pierie JEN; Plat VD; Rosman C; Ruurda JP; van Sandick JW; Sosef MN; Voeten DM; Vijgen GHEJ; Bijlsma MF; Meijer SL; Hulshof MCCM; Oyarce C; Lagarde SM; van Laarhoven HWM; van Berge Henegouwen MI;
Br J Surg; 2024 Jan; 111(2):. PubMed ID: 38387083
[TBL] [Abstract][Full Text] [Related]
22. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.
Soeratram TT; Creemers A; Meijer SL; de Boer OJ; Vos W; Hooijer GK; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; Lei M; Bijlsma MF; Ylstra B; van Grieken NC; van Laarhoven HW
J Pathol; 2022 Mar; 256(3):282-296. PubMed ID: 34743329
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
Kamarajah SK; Phillips AW; Ferri L; Hofstetter WL; Markar SR
Br J Surg; 2021 Apr; 108(4):403-411. PubMed ID: 33755097
[TBL] [Abstract][Full Text] [Related]
24. Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients.
Dijksterhuis WPM; Hulshoff JB; van Dullemen HM; Kats-Ugurlu G; Burgerhof JGM; Korteweg T; Mul VEM; Hospers GAP; Plukker JTM
Acta Oncol; 2019 Nov; 58(11):1640-1647. PubMed ID: 31397195
[No Abstract] [Full Text] [Related]
25. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.
Hulshoff JB; Faiz Z; Karrenbeld A; Kats-Ugurlu G; Burgerhof JG; Smit JK; Plukker JT
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1301-9. PubMed ID: 26314875
[TBL] [Abstract][Full Text] [Related]
27. Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma.
Kathiravetpillai N; Koëter M; van der Sangen MJ; Creemers GJ; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
Eur J Surg Oncol; 2016 Aug; 42(8):1183-90. PubMed ID: 27134188
[TBL] [Abstract][Full Text] [Related]
28. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
[TBL] [Abstract][Full Text] [Related]
29. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Klevebro F; Alexandersson von Döbeln G; Wang N; Johnsen G; Jacobsen AB; Friesland S; Hatlevoll I; Glenjen NI; Lind P; Tsai JA; Lundell L; Nilsson M
Ann Oncol; 2016 Apr; 27(4):660-7. PubMed ID: 26782957
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of Pretreatment Pathological Tumor Extent in Patients Treated With Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal or Junctional Cancer.
Shapiro J; Biermann K; van Klaveren D; Offerhaus GJ; Ten Kate FJ; Meijer SL; van Berge Henegouwen MI; Steyerberg EW; Wijnhoven BP; Lanschot JJ
Ann Surg; 2017 Feb; 265(2):356-362. PubMed ID: 28059964
[TBL] [Abstract][Full Text] [Related]
31. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
[TBL] [Abstract][Full Text] [Related]
32. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis.
Hölscher AH; Bollschweiler E; Bogoevski D; Schmidt H; Semrau R; Izbicki JR
Eur J Cancer; 2014 Nov; 50(17):2950-7. PubMed ID: 25307749
[TBL] [Abstract][Full Text] [Related]
35. Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial.
Robb WB; Dahan L; Mornex F; Maillard E; Thomas PA; Meunier B; Boige V; Pezet D; Le Brun-Ly V; Bosset JF; Mabrut JY; Triboulet JP; Bedenne L; Seitz JF; Mariette C;
Ann Surg; 2015 May; 261(5):902-8. PubMed ID: 25361220
[TBL] [Abstract][Full Text] [Related]
36. [Application value of texture analysis of magnetic resonance images in prediction of neoadjuvant chemoradiotherapy efficacy for rectal cancer].
Shu Z; Fang S; Ding Z; Mao D; Pang P; Gong X
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1051-1058. PubMed ID: 30269327
[TBL] [Abstract][Full Text] [Related]
37. Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma Patients With or Without Neoadjuvant Chemoradiotherapy.
Noordman BJ; van Klaveren D; van Berge Henegouwen MI; Wijnhoven BPL; Gisbertz SS; Lagarde SM; van der Gaast A; Hulshof MCCM; Biermann K; Steyerberg EW; van Lanschot JJB;
Ann Surg; 2018 May; 267(5):892-897. PubMed ID: 28350565
[TBL] [Abstract][Full Text] [Related]
38. A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy.
Dunne B; Reynolds JV; Mulligan E; Kelly A; Griffin M
J Clin Pathol; 2001 Nov; 54(11):841-5. PubMed ID: 11684717
[TBL] [Abstract][Full Text] [Related]
39. Prognostic implications of the extent of downstaging after neoadjuvant therapy for oesophageal adenocarcinoma and oesophageal squamous cell carcinoma.
Kamarajah SK; Markar SR; Low D; Phillips AW
BJS Open; 2023 May; 7(3):. PubMed ID: 37341158
[TBL] [Abstract][Full Text] [Related]
40. External validation of 18 F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy.
Valkema MJ; Beukinga RJ; Chatterjee A; Woodruff HC; van Klaveren D; Noordzij W; Valkema R; Bennink RJ; Roef MJ; Schreurs W; Doukas M; Lagarde SM; Wijnhoven BPL; Lambin P; Plukker JTM; van Lanschot JJB
Nucl Med Commun; 2023 Aug; 44(8):709-718. PubMed ID: 37132272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
